NASDAQ · Medical - Pharmaceuticals

KYNB (KYNB) Stock

$7.27 +4.15% NASDAQ: KYNB Healthcare

Valuation

MetricValue
Price$7.27
Market Cap$29.43M
P/E Ratio0.16
P/B Ratio7.22
P/S Ratio4.82
EPS (TTM)$45.37
52-Week High$12.60
52-Week Low$4.85
Dividend Yield—

Financials & Margins

MetricValue
ROE4575.00%
ROA152.50%
ROCE-920.00%
Gross Margin-766.67%
Operating Margin-766.67%
Net Margin3050.00%
Debt/Equity0.00
Current Ratio3.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$235.0M$141.0M$47.0M$30.0M$6.0M
Operating Profit$-289.0M$-301.0M$-323.0M$-150.0M$-46.0M
Net Profit$-290.0M$-294.0M$-284.0M$-48.0M$183.0M
EPS$-3.15$-3.15$-2.92$-0.48$45.37
Op Margin-122.6%-213.9%-689.5%-507.8%-712.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$774.0M$610.0M$424.0M$215.0M$120.0M
Total Liabilities$545.0M$612.0M$586.0M$398.0M$115.0M
Cash$171.0M$156.0M$114.0M$50.0M$48.0M
Borrowings$100.0M$90.0M$170.0M$90.0M$0

Latest News

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates Zacks · Jul 23, 2026 Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes GlobeNewswire · Jun 11, 2026 Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca MT Newswires · Jun 10, 2026 Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ... GuruFocus.com · May 12, 2026 Kyntra Bio (KYNB) Q1 2026 Earnings Transcript Motley Fool · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$-146.0M$-315.0M$-138.0M$-5.0M
Investing Cash Flow$-457.0M$50.0M$151.0M$126.0M$35.0M
Financing Cash Flow$-7.0M$43.0M$1.0M$2.0M$-82.0M
Net Cash Flow$-507.0M$-16.0M$-42.0M$-12.0M$-54.0M
Free Cash Flow$-112.0M$-185.0M$-318.0M$-138.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-17.30%
Quick Ratio3.28
Interest Coverage-5.11
Return 1Y0.68%
Return 3Y-88.57%
Return 5Y-97.95%

Ownership

Insiders Held2.02%
Institutions Held25.57%
Institutions Float Held26.10%
Institutional HolderSharesReport Date
Armistice Capital, LLC400,0002026-03-31
Vanguard Capital Management LLC156,6072026-03-31
Acadian Asset Management. LLC105,5852026-03-31
Blackrock Inc.84,3312026-03-31
Two Sigma Investments, LP49,5112026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About KYNB

KYNB is led by CEO Thane Wettig, publicly traded since 2014.

KYNB stock trades at $7.27 with a market capitalization of $29.43M. The stock is valued at a price-to-earnings (P/E) ratio of 0.16, price-to-book of 7.22, price-to-sales of 4.82. Over the past 52 weeks the stock has ranged between $4.85 and $12.60, and currently trades 42.3% below its 52-week high.

On profitability, KYNB generates a return on equity (ROE) of 4575.00% — well above the market average, a sign of a high-quality business, return on capital employed of -920.00%, an operating margin of -766.67%, a net profit margin of 3050.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides